Apollomics (APLM) Operating Leases (2020 - 2025)

Apollomics (APLM) posted quarterly Operating Leases of $434000.0 for Q4 2025, up 15.12% quarter-over-quarter from $377000.0 in Q4 2022.

Apollomics (APLM) Operating Leases (2020 - 2025) Analysis & Trends

Apollomics (APLM) has reported Operating Leases for 4 consecutive years, with $434000.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Operating Leases changed N/A year-over-year to $434000.0; the TTM figure through Dec 2025 stood at $434000.0 (changed N/A YoY), while the FY2025 annual figure was $434000.0, changed N/A from the prior year.
Operating Leases improved to $434000.0 in Q4 2025 per APLM's latest filing, from $377000.0 in the prior quarter.
Across five years, Operating Leases topped out at $1.0 million in Q4 2021 and bottomed at $377000.0 in Q4 2022.
Historically, Operating Leases has averaged $604500.0 across 3 years, with a median of $502500.0 in 2022.
Annual changes were most pronounced in 2021 — Operating Leases surged 235.28% — and 2022, when it plunged 63.61%.
Apollomics' Operating Leases stood at $1.0 million in 2021, then slumped by 63.61% to $377000.0 in 2022, then gained by 15.12% to $434000.0 in 2025.
Business Quant data shows APLM's Operating Leases at $434000.0 in Q4 2025, $377000.0 in Q4 2022, and $571000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Apollomics	34.08 Mn	30.81 Mn	-

Download Data